Biocon diversifies business model, enters digital therapeutic segment

To launch Insulia for at-home management of diabetes in collaboration with Voluntis

Going beyond medicine, biopharmaceutical major Biocon has diversified and entered the digital therapeutic segment as part of its global strategy. 

The Bengaluru-based company’s Malaysian subsidiary has collaborated with France-based healthcare solutions company Voluntis to develop and distribute a digital product for diabetic patients.

“We see the world evolving after Covid. Technology and digital will play a major role in our strategy because it will bring costs significantly down in the healthcare systems,” said Christiane Hamacher, CEO and Managing Director, Biocon Biologics.

The product, called Insulia, provides automated insulin dose recommendations and messages for people with diabetes while enabling the healthcare